Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Belite Bio, Inc. ADR ( (BLTE) ) is now available.
On April 21, 2026, Belite Bio, Inc. announced it had begun a rolling submission of a New Drug Application to the U.S. Food and Drug Administration for tinlarebant, an oral therapy for Stargardt disease type 1 that has received Breakthrough Therapy Designation. The company, which expects to complete the filing in the second quarter of 2026, highlighted pivotal Phase 3 DRAGON data and is simultaneously ramping up commercialization preparations, including building sales, market access, medical and operational teams, underscoring tinlarebant’s potential to become the first approved treatment for this rare inherited retinal disorder and a key value driver for stakeholders.
Belite executives framed the NDA milestone as a major step for patients, caregivers and physicians facing a disease that often leads to legal blindness in adolescence. The move also signals Belite’s transition from pure clinical development toward a commercial-stage posture, as it works closely with the FDA on the review process and positions tinlarebant to anchor its strategy in the competitive retinal disease market.
The most recent analyst rating on (BLTE) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Belite Bio, Inc. ADR stock, see the BLTE Stock Forecast page.
Spark’s Take on BLTE Stock
According to Spark, TipRanks’ AI Analyst, BLTE is a Neutral.
Score is driven primarily by strong balance-sheet strength and a constructive earnings-call backdrop (Phase III success, defined NDA/launch timeline, and materially improved cash runway). This is tempered by pre-revenue financial performance with accelerating losses/cash burn, mixed technical signals, and limited support from traditional valuation metrics due to negative earnings and no dividend.
To see Spark’s full report on BLTE stock, click here.
More about Belite Bio, Inc. ADR
Belite Bio, Inc. is a NASDAQ-listed clinical-stage drug development company focused on novel therapeutics for degenerative retinal diseases with high unmet medical need, including Stargardt disease type 1 (STGD1) and geographic atrophy in advanced dry age-related macular degeneration, as well as certain metabolic disorders. Its lead oral candidate, tinlarebant, aims to reduce bisretinoid toxin buildup in the eye and is in late-stage clinical trials, including the completed Phase 3 DRAGON study in adolescent STGD1 and ongoing DRAGON II and PHOENIX trials.
Average Trading Volume: 187,198
Technical Sentiment Signal: Buy
Current Market Cap: $6.74B
See more data about BLTE stock on TipRanks’ Stock Analysis page.